In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $381M in funding, enter new partnerships, announce regulatory milestones, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Received FDA Breakthrough Device Designation for its AI-powered hyperkalemia detection software using Lead I ECG data. This designation will accelerate the development of its solution aimed at enabling early detection of moderate to severe episodes of hyperkalemia.
Announced the initial close of a Series A funding round led by Varana Capital to support the company’s next phase of growth. Arcuro develops the SuperBall Meniscal Repair System, an all-inside, all-suture, knotless device designed to mimic inside-out tensioning of the meniscus.
Raised $115M in a Series B funding round led by Dimension to advance its bioprinted tissue therapeutics platform. The company plans to use the funds to accelerate clinical development of several of its regenerative medicine solutions.
LSI Alumni Caresyntax and Qaelon Medical partnered to address the devastating impact of surgical leaks. Through this collaboration, Caresyntax’s surgical intelligence platform will integrate with Qaelon’s innovative leak detection technology to enhance surgical outcomes.
LSI Alumni Caresyntax and Roivios joined forces to revolutionize renal care through data-driven insights. This collaboration focuses on Roivios’ JuxtaFlow Renal Assist Device (RAD) trial, with Caresyntax’s platform supporting real-time evidence to improve patient outcomes.
Closed a $120M equity funding round to accelerate commercial growth. The funds will help the company expand the availability of its four-day wearable insulin delivery devices for patients living with diabetes.
Secured $80M in oversubscribed Series C equity financing to advance its water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer. The financing will support ongoing clinical trials and commercial scaling efforts.
Appointed Eric Davidson as Chief Commercial Officer to lead commercial strategy and execution. Davidson’s extensive experience in medical robotics will support the company as it prepares for market entry.
Appointed Drew Trivisonno to its Board of Directors. Trivisonno’s financial and business development expertise will support the company’s funding efforts and expansion in the U.S. orthopedics market.
Welcomed Anna Nestor to its leadership team as a VP of Quality. With over two decades of experience, Nestor will support the company as it develops quality systems for its SteriCISION C-Section Retractor.
Appointed Maria Sainz as Chair of its Board of Directors. Sainz brings extensive leadership experience and a proven track record in scaling medtech companies, which will help steer Onera’s growth in sleep diagnostics and monitoring.
Completed its first-in-human cases using its NanoCEPT antibacterial technology to help reduce infection risk in orthopedic implants. The company also secured a $35M venture loan facility from Horizon Technology Finance to expedite manufacturing and commercialization.
Announced a name change from Prana Thoracic to Prana Surgical to align with its strategic vision. The company plans to expand its solutions beyond the lungs and into a broader range of medical needs.
Announced that its Summit platform secured a Defense Logistics Agency (DLA) ECAT contract. The company’s Summit platform combines single-use endoscopes with cloud-based software to improve minimally invasive visualization.
Announced the acquisition of BioMediq A/S to expand its breast cancer risk assessment capabilities. This acquisition aims to provide breast cancer assessment capabilities to ScreenPoint’s flagship product, Transpara.
Received IDE approval from the FDA for its Acolyte Catheter System and 510(k) clearance for its Shadow Catheter. The company also welcomed William N. Starling to its Board of Directors in October of 2024.
Appointed Dan Hughes as its Commercial Lead. With over 30 years of experience in medical device sales, Hughes will lead the company’s U.S. launch with its distribution partners and build the commercial strategy for its biopsy closure device.
Appointed Brad Davis as Chief Commercial Officer and Bill Kelly as Chief Financial Officer. The leadership additions will support SpectraWAVE’s in expanding its product portfolio and commercial footprint.
Successfully completed its first-in-human trial for its Spiro-Vista tracheal intubation device. In the trial of 30 patients with highly challenging and complex airways, all were successfully intubated on the first attempt without complications or adverse events.
Appointed Allen Meacham as its new CEO to lead the company’s growth and innovation efforts. He brings extensive neuromodulation experience to support the ongoing ReInvigorate clinical trial for the pdSTIM System.
Announced the first use of Medacta International’s GMK Sphere implant with its TMINI Miniature Robotic System. The GMK Sphere and SpheriKA systems are the only medial Ball-in-Socket design knee systems available for use with the TMINI system.
Closed its third fund, raising $425M to invest in breakthrough medical technology companies. The new fund will support innovative startups focused on improving patient care through advanced medical solutions.
Appointed Bob Gerberich as Chief Commercial Officer for North America. Gerberich will lead the company’s U.S. pre-launch market development and commercialization efforts, spearheading the adoption of Vitestro’s technology within the U.S. market.
Expanded its global footprint in the U.S. market via its launch of a new subsidiary in California. The move supports upcoming U.S.-based clinical trials to validate its Axana device, a portable stroke imaging and detection system.
Completed enrollment in its EU pivotal trial for its aXess technology and is preparing for market approval. aXess is a restorative vascular access conduit designed to improve the dialysis patient experience while avoiding frequent reinterventions.
Secured $31M in a Series B funding round to advance its wireless EEG headset and cloud platform. This latest funding will allow the company to grow its commercial and operational teams, accelerate expansion, and bolster its ongoing research and development initiatives.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
